Payment overview · 2025
General Payments
$2,056.39
47 reported records · 15 companies
Healthcare provider profile · identity verified
William C Ta, M.D.
Allopathic & Osteopathic Physicians|General Practice · HOOPA, CA · NPI 1790955300
Verified facts
What the public records show
CMS Open Payments records show William C Ta, M.D. received $2,056.39 in general payments during 2025 across 47 reported records.
Novo Nordisk Inc accounted for 19.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Kerendia, Ozempic, Rybelsus.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $404.09 | 19.6% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $298.92 | 14.5% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $253.08 | 12.3% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $222.60 | 10.8% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $212.64 | 10.3% | 4 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $201.73 | 9.8% | 4 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $148.25 | 7.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $116.15 | 5.7% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $73.75 | 3.6% | 3 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $28.72 | 1.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.95 | 1.1% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $19.63 | 0.9% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $19.56 | 0.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $18.82 | 0.9% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $16.50 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,056.39 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $283.95 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $269.67 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $231.15 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $222.60 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $212.64 | 4 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $201.73 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $175.86 | 7 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $148.25 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $122.07 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $120.14 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $116.15 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $73.75 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $40.63 | 2 | 2025 |
Source payment records
|
|||||
| SPINRAZA Normalized: spinraza |
Biological | Biogen, Inc. | $28.72 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.95 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.95 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $19.63 | 1 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 72 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 158 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
178 | 44 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
158 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
72 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 433 | 124 |
| Amlodipine Besylate | Amlodipine Besylate | 374 | 107 |
| Metformin Hcl | Metformin Hcl | 273 | 77 |
| Omeprazole | Omeprazole | 234 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 200 | 50 |
| Simvastatin | Simvastatin | 192 | 59 |
| Lisinopril | Lisinopril | 183 | 60 |
| Gabapentin | Gabapentin | 178 | 45 |
| Jardiance | Empagliflozin | 178 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 166 | 50 |
| Ozempic | Semaglutide | 158 | 32 |
| Glipizide | Glipizide | 144 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 38 |
| Ibuprofen | Ibuprofen | 128 | 44 |
| Meloxicam | Meloxicam | 125 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 121 | 31 |
| Losartan Potassium | Losartan Potassium | 119 | 45 |
| Metformin Hcl Er | Metformin Hcl | 108 | 30 |
| Famotidine | Famotidine | 94 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 83 | 23 |
| Furosemide | Furosemide | 82 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 79 | 24 |
| Clonidine Hcl | Clonidine Hcl | 76 | 25 |
| Baclofen | Baclofen | 72 | 25 |
| Eliquis | Apixaban | 72 | suppressed |
| Azithromycin | Azithromycin | 70 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 70 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 12 |
| Trazodone Hcl | Trazodone Hcl | 57 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 12 |
| Sertraline Hcl | Sertraline Hcl | 49 | 12 |
| Donepezil Hcl | Donepezil Hcl | 48 | 16 |
| Montelukast Sodium | Montelukast Sodium | 45 | 11 |
| Alendronate Sodium | Alendronate Sodium | 41 | 14 |
| Ezetimibe | Ezetimibe | 41 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 41 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 40 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | 11 |
| Januvia | Sitagliptin Phosphate | 38 | 11 |
| Naproxen | Naproxen | 38 | 14 |
| Tramadol Hcl | Tramadol Hcl | 37 | 12 |
| Vascepa | Icosapent Ethyl | 37 | 14 |
| Valsartan | Valsartan | 35 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 32 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | suppressed |
| Mupirocin | Mupirocin | 31 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | 11 |
| Atenolol | Atenolol | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | 11 |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | suppressed |
| Carvedilol | Carvedilol | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Allopurinol | Allopurinol | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | 11 |
| Prednisone | Prednisone | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Kerendia | Finerenone | 15 | suppressed |
| Sulfasalazine | Sulfasalazine | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Potassium Chloride | Potassium Chloride | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,056.39 · 47 records | Novo Nordisk Inc | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), ELIQUIS, IBSRELA, ImmunoCAP, JOURNAVX, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, PYRUKYND, QULIPTA, Rybelsus, SPINRAZA, The Cologuard Plus Collection Kit, UBRELVY, Wegovy, ZENPEP, ZEPBOUND, ZORYVE, ZTLido | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error